Lund-based company Spago Nanomedical recently announced interim results from their phase I study with SpagoPix, the tumour selective contrast agent in cancer diagnostics with magnetic resonance imaging. The results show that the candidate is safe, that it accumulates into the tumours, and that it provides clear contrast enhancement in the image analysis. Based on these results the company has decided to expand the study to new indications, in addition to breast cancer. BioStock reached out to CEO Mats Hansen for a comment.

Read the interview with Spago Nanomedical's CEO Mats Hansen at biostock.se:

https://www.biostock.se/en/2022/01/positive-interim-results-from-spago-nanomedical/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

https://news.cision.com/spago/r/biostock--positive-interim-results-from-spago-nanomedical,c3486479

(c) 2022 Cision. All rights reserved., source Press Releases - English